April 30th 2025
Novavax continues working with FDA, but case could signal a shift in broader vaccine procedures.
April 17th 2025
Moves prompt praise from opponents of high costs of medications, PBMs.
April 9th 2025
Are your patients' medications about to get more expensive?
March 26th 2025
As obesity medications gain popularity, many older Americans support coverage — but not higher premiums.
Policy center argues patients around the world benefit when Americans pay more than their fair share for research and medicines.
IVF, cancer, prescription drugs among health care issues in president’s State of the Union 2024 address
Abortion and AI also in the mix at the national level.
President, Big Pharma, PBMs wrangle over high drug prices
Critics air concerns at White House roundtable as pharmacy benefit manager volley back.
Congress needs to crack down on PBMs, state attorneys general say
More than half of the nation’s state top lawyers pen letter to leaders in House and Senate.
Medicare to cap out-of-pocket spending on Part D prescription drugs at $2,000
Change takes effect in 2025 and could benefit more than one million Medicare beneficiaries
Medicare drug price negotiations could hurt patients by disincentivizing research
PhRMA, U.S. Chamber warn of unintended consequences, market effects of negotiations.
CMS kicks off price negotiations with Big Pharma for 10 drugs for Medicare
Administration, HHS tout milestone day on road to lowering drug prices for beneficiaries.
Pharma CEO: Let's have transparency in prescription drug pricing
It's time for pharmaceutical companies and others to innovate and disrupt the distribution side of treatment.
Medicare leaders target PBMs, insurance coverage, pharmacy competition
Prescription drug prices, vaccine costs are also key issues.
Prescription drug rebates are coming: CMS
In 2024, beneficiaries could see savings per dose, according to new guidance on price increases relative to inflation.
President targets high prescription drug prices with ‘march-in’ authority
Public-private partnerships will crumble, hurting drug innovation and eventually patients, Republicans say.